JIH-JONG LEEChristine S. HughesRobert L. FineRodney L. Page2018-09-102018-09-101996-051892-1898http://scholars.lib.ntu.edu.tw/handle/123456789/324817https://www2.scopus.com/inward/record.uri?eid=2-s2.0-0029965253&doi=10.1002%2f%28SICI%291097-0142%2819960501%2977%3a9%3c1892%3a%3aAID-CNCR20%3e3.0.CO%3b2-U&partnerID=40&md5=422c18b9fe3fccb072d6ddfd958f68ecBACKGROUND. Despite extensive investigation, the role of MDR of human cancer remains unclear. Canine lymphoma is a spontaneously arising correlate of human non-Hodgkin's lymphoma that may complement other in vivo models for investigation of issues related to MDR. METHODS. Immunoreactivity of primary antibodies to the human MDR1 gene product, p-glycoprotein 170 (Pgp), were determined in both a retrospective (n = 76) and prospective (n = 15) survey of canine lymphoma. Known prognostic factors and response to chemotherapy were correlated with categorical designations of Pgp expression. RESULTS. When combined, 61 of 91 samples (67%) were negative for Pgp, 16 of 91 (17.5%) had strong Pgp immunoreactivity in >50% of the malignant population and 14 of 91 (15.5%) had Pgp reactivity in 10-50% of cells. Pgp expression was greater after relapse compared with pretreatment samples [C494 83% vs. 25%; P = 0.012 and C219 73% vs. 27%; P = 0.04]. Pretreatment Pgp expression was an independent negative predictor of overall survival (median = 225d vs. 367d; P = 0.02). CONCLUSIONS. Pgp expression in spontaneous canine lymphoma is similar to that reported in human non-Hodgkin's lymphoma. Use of this model may expedite investigation of novel strategies for MDR prevention or modulation.canine; lymphoma; multidrug resistance; P-glycoprotein[SDGs]SDG3glycoprotein p; animal cell; animal model; animal tissue; article; controlled study; dog; gene expression regulation; immunoreactivity; lymphoma; multidrug resistance; nonhodgkin lymphoma; nonhuman; priority journal; prognosis; protein determination; Animals; Antibodies, Monoclonal; Disease Models, Animal; Dog Diseases; Dogs; Drug Resistance, Neoplasm; Forecasting; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; P-Glycoprotein; Phenotype; Prognosis; Prospective Studies; Retrospective Studies; Survival Ratejournal article10.1002/(sici)1097-0142(19960501)77:9<189210.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U2-s2.0-0029965253